ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares reached a new 52-week high on Monday . The company traded as high as $70.92 and last traded at $70.08, with a volume of 63,292 shares trading hands. The stock had previously closed at $69.58.

A number of analysts have commented on ANIP shares. Guggenheim reissued a “buy” rating and issued a $80.00 target price (up previously from $65.00) on shares of ANI Pharmaceuticals in a report on Friday, August 5th. Oppenheimer Holdings Inc. lifted their target price on ANI Pharmaceuticals from $65.00 to $71.00 and gave the stock an “outperform” rating in a report on Friday, August 5th. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 target price for the company in a report on Wednesday, July 20th. Citigroup Inc. raised ANI Pharmaceuticals to an “outperform” rating and set a $65.00 target price for the company in a report on Tuesday, July 19th. Finally, Raymond James Financial Inc. started coverage on ANI Pharmaceuticals in a report on Wednesday, June 22nd. They issued a “strong-buy” rating and a $68.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. ANI Pharmaceuticals has a consensus rating of “Buy” and an average price target of $64.00.

The stock has a market capitalization of $803.56 million and a P/E ratio of 82.01. The company has a 50 day moving average of $59.61 and a 200 day moving average of $45.86.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.34. The firm earned $31.30 million during the quarter, compared to analysts’ expectations of $27.63 million. During the same quarter in the previous year, the firm posted $0.55 EPS. The firm’s revenue for the quarter was up 60.5% on a year-over-year basis. On average, equities research analysts forecast that ANI Pharmaceuticals Inc. will post $4.12 EPS for the current fiscal year.

In related news, VP Robert W. Schrepfer sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $67.06, for a total value of $838,250.00. Following the completion of the sale, the vice president now owns 17,362 shares in the company, valued at $1,164,295.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

A hedge fund recently raised its stake in ANI Pharmaceuticals stock. Mutual of America Capital Management LLC increased its position in ANI Pharmaceuticals Inc. (NASDAQ:ANIP) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,178 shares of the specialty pharmaceutical company’s stock after buying an additional 178 shares during the period. Mutual of America Capital Management LLC owned approximately 0.26% of ANI Pharmaceuticals worth $1,362,000 at the end of the most recent reporting period.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.